Advanced search
Publication Cover
Future Oncology Volume 12, 2016 - Issue 23
Submit an article Journal homepage
463
Views
0
CrossRef citations to date
0
Altmetric
Short Communication

Ipilimumab After Progression on Anti-Pd-1 Treatment in Advanced Melanoma

Francisco Aya1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, SpainCorrespondence[email protected]
,
Lydia Gaba1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
,
Iván Victoria1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
,
Aranzazu Fernández-Martínez1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
,
Mónica Tosca1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
,
Aleix Prat1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
&
Ana Arance1 Medical Oncology Department, Hospital Clinic Barcelona, Villaroel 170, 08036Barcelona, Spain;2 Targeted Therapeutics & Translational Genomics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)Barcelona, Spain
 show all
Pages 2683-2688 | Received 20 Jan 2016, Accepted 26 Jun 2016, Published online: 01 Sep 2016

References

  • John L , CoweyCL. The rapid emergence of novel therapeutics in advanced malignant melanoma. Dermatol. Ther. (Heidelb.)5(3), 151–169 (2015).
  • Naidoo J , PageDB, LiBTet al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann. Oncol.26(12), 2375–2391 (2015).
  • Schadendorf D , HodiFS, RobertCet al. Pooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol.33(17), 1889–1894 (2015).
  • Robert C , LongGV, BradyBet al. Nivolumab in previously untreated melanoma without BRAF mutation. N. Engl. J. Med.372(4), 320–330 (2015).
  • Weber JS , D’AngeloSP, MinorDet al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, Phase 3 trial. Lancet Oncol.16(4), 375–384 (2015).
  • Ribas A , PuzanovI, DummerRet al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, Phase 2 trial. Lancet Oncol.16(8), 908–918 (2015).
  • Eisenhauer EA , TherasseP, BogaertsJet al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur. J. Cancer45(2), 228–247 (2009).
  • Institute NC . Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-2006-14_QuickReference_5x7.pdf.
  • Parry RV , ChemnitzJM, FrauwirthKAet al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol. Cell. Biol.25(21), 9543–9553 (2005).
  • Curran MA , MontalvoW, YagitaH, AllisonJP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc. Natl Acad. Sci. USA107(9), 4275–4280 (2010).
  • Selby M , EngelhardtJ, LuL-S. Antitumor activity of concurrent blockade of immune checkpoint molecules CTLA-4 and PD-1 in preclinical models. J. Clin. Oncol.31 (2013).
  • Hamid O , RobertC, DaudAet al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med.369(2), 134–144 (2013).
  • Postow MA , ChesneyJ, PavlickACet al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N. Engl. J. Med.372(21), 2006–2017 (2015).
  • Larkin J HF , WolchokJD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.373(13), 1270–1271 (2015).
  • Hodi FS , O’DaySJ, McDermottDFet al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med.363(8), 711–723 (2010).
  • Hodi FS , GibneyG, SullivanRet al. ( Eds). An open-label, randomized, Phase 2 study of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064). Presented at: European Cancer Congress (ECC). Vienna, Austria, 25–29 September 2015.
  • Weber JS , YangJC, AtkinsMB, DisisML. Toxicities of immunotherapy for the practitioner. J. Clin. Oncol.33(18), 2092–2099 (2015).
  • Liakou CI , KamatA, TangDNet al. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc. Natl Acad. Sci. USA105(39), 14987–14992 (2008).
  • Keir ME , ButteMJ, FreemanGJ, SharpeAH. PD-1 and its ligands in tolerance and immunity. Ann. Rev. Immunol.26, 677–704 (2008).
  • Prithviraj P , McArthurG, AtkinsonVet al. Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy. J. Immunother. Cancer3(Suppl. 2), P126 (2015).
  • Prithviraj P , McArthurGA, AtkinsonV. Efficacy and toxicity of treatment with the anti-CTLA-4 antibody Ipilimumab in patients with metastatic melanoma who have progressed on anti-PD-1 therapy. J. Clin. Oncol.33(Suppl.), Abstract 9059 (2015).
  • Danlos FX , PagesC, RouxJet al. Atypical severe immune-related adverse effects resulting from sequenced immunotherapy in melanoma. Melanoma Res.25(2), 178–179 (2015).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.